{
  "slug": "origami-therapeutics-inc",
  "name": "Origami Therapeutics, Inc.",
  "yc_id": 26122,
  "batch": "Winter 2022",
  "website": "http://origamitherapeutics.com",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:15:43.453362",
    "website": "http://origamitherapeutics.com",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 6261.91,
      "final_url": "https://origamitherapeutics.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:15:49.715291"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "origamitherapeutics.com",
      "registrar": "Squarespace Domains II LLC",
      "creation_date": "2015-06-21T17:51:16",
      "expiration_date": "2026-06-21T17:51:16",
      "domain_age_days": 3770,
      "domain_age_years": 10.3,
      "name_servers": [
        "NS.INMOTIONHOSTING.COM",
        "NS2.INMOTIONHOSTING.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": false,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 0,
      "server": "Apache"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:46.251058",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:54:22.839355",
    "market_analysis": {
      "market_size": "large",
      "market_stage": "growing",
      "key_trends": [
        "Increasing focus on protein degradation therapies",
        "Growing neurodegeneration patient population",
        "Shift toward precision medicine in rare diseases"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary human disease models for drug selection and protein degrader platform technology",
      "differentiation": "Focus on oral protein degraders with human-validated disease models for neurodegeneration",
      "competitive_advantages": [
        "Proprietary disease models for better clinical translation",
        "Oral delivery advantage over injectable competitors"
      ],
      "competitive_vulnerabilities": [
        "Large pharma competition with deeper resources",
        "Dependence on single indication (Huntington's) initially"
      ]
    },
    "business_model": {
      "revenue_model": "Biotech licensing/partnership",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Small molecule identification completed",
        "Y Combinator validation",
        "Established domain presence"
      ],
      "growth_bottlenecks": [
        "Clinical trial funding requirements",
        "Regulatory approval timeline",
        "Small team size for biotech operations"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Clinical trial failure risk",
        "Long development timelines (10+ years)",
        "High capital requirements for drug development"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Novel protein degrader approach",
        "Addressing unmet medical need in neurodegeneration",
        "Proprietary platform with multiple indication potential"
      ],
      "concerns": [
        "Early stage with unproven clinical efficacy",
        "High capital intensity typical of biotech"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Arvinas",
        "C4 Therapeutics"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure Series A funding for IND-enabling studies",
        "Expand team with clinical development expertise"
      ],
      "expansion_opportunities": [
        "Apply platform to other neurodegenerative diseases",
        "Explore strategic partnerships with big pharma"
      ]
    },
    "tokens_used": {
      "input": 728,
      "output": 575,
      "total": 1303,
      "estimated_cost": 0.010809
    },
    "status": "success"
  },
  "phase8_complete": true
}